Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial of APG808, the company’s anti-inflammatory injection therapy for chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory disorders. “Launching our second clinical program, ahead of initial timeline expectations, brings us one step closer to providing…
Out-of-pocket costs for AstraZeneca’s inhaled respiratory therapies — most of which are used for chronic obstructive pulmonary disease (COPD) — will be capped at $35 per month for eligible patients in the U.S. starting in June, the company announced in a press release. This cap, likely to…
A Phase 3 clinical trial assessing the potential of triple-combination Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to improve cardiopulmonary outcomes in people with chronic obstructive pulmonary disease (COPD) is opening at sites worldwide, AstraZeneca, which markets the inhaled therapy, announced. The THARROS study (NCT06283966) is expected to enroll up…
A first patient has been treated in a pivotal clinical trial of Pulmonx’s AeriSeal System, testing its ability to limit collateral ventilation in people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). These patients currently are precluded from using the company’s minimally invasive…
The first patient has been dosed in a Phase 2a clinical trial testing ReAlta Life Sciences’ RLS-0071 in adults with chronic obstructive pulmonary disease (COPD) who are experiencing acute exacerbations, or sudden symptom worsening. The trial (NCT06175065) will evaluate the safety of RLS-0071 versus a placebo in…
The U.S. Food and Drug Administration has agreed to review Sanofi and Regeneron Pharmaceuticals’ request for a label extension for Dupixent (dupilumab) to include it as an add-on treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). The therapy’s potential sixth indication in the U.S.
The U.S. Food and Drug Administration (FDA) for the first time has cleared a fingertip pulse oximeter for home use as a medical device that consumers — including people with chronic obstructive pulmonary disease (COPD) — can use to check their blood oxygen levels. The device, MightySat Medical from…
Travel times limit access to pulmonary rehabilitation programs to help people with chronic lung conditions, such as chronic obstructive pulmonary disease (COPD), a U.S. report revealed. Data showed about 80% of people live within a 30-minute drive of a rehabilitation site, mostly those who reside within major urban and…
A Phase 2a clinical trial of AstraZeneca’s experimental therapy mitiperstat is now recruiting adults with moderate to severe chronic obstructive pulmonary disease (COPD) at a study site in Choctaw, Oklahoma. The Care Access research site is among nearly 20 study centers in the U.S., located across 11…
Pulmonary (lung) rehabilitation nearly halves the odds of people with chronic obstructive pulmonary disease (COPD) experiencing an exacerbation, and it also cuts the risk of dying by about one-third, a study in Korea found. The study, “Pulmonary Rehabilitation Is Associated With Decreased Exacerbation and Mortality in Patients With…
Get regular updates to your inbox.